Clinical Trial Update: A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma [Phase 3]

View source ↗

Summary

A Phase 3 study comparing JNJ-79635322 and Teclistamab in relapsed or refractory multiple myeloma is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• JNJ-79635322
• TECVAYLI (TECLISTAMAB-CQYV)

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Multiple Myeloma | Phase 3 | Status: NOT_YET_RECRUITING